Compare · NVO vs PTIX
NVO vs PTIX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Protagenic Therapeutics Inc. (PTIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PTIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 11552.1x PTIX ($18.7M).
- Over the past year, NVO is down 12.1% and PTIX is down 81.7% - NVO leads by 69.6 points.
- PTIX has been more active in the news (12 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for PTIX).
- Company
- Novo Nordisk A/S
- Protagenic Therapeutics Inc.
- Price
- $48.65+3.65%
- $0.73-44.06%
- Market cap
- $215.46B
- $18.7M
- 1M return
- -2.08%
- +0.00%
- 1Y return
- -12.07%
- -81.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Protagenic Therapeutics Inc.
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PTIX
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $13,000 worth of shares (20,000 units at $0.65), increasing direct ownership by 37% to 73,533 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $9,811 worth of shares (16,634 units at $0.59), increasing direct ownership by 45% to 53,533 units (SEC Form 4)
- Protagenic Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $945 worth of shares (2,700 units at $0.35), increasing direct ownership by 8% to 36,899 units (SEC Form 4)
- Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
- SEC Form 10-Q filed by Protagenic Therapeutics Inc.
- SEC Form NT 10-Q filed by Protagenic Therapeutics Inc.
- SEC Form 10-K filed by Protagenic Therapeutics Inc.
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $710 worth of shares (2,220 units at $0.32), increasing direct ownership by 7% to 34,199 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $151 worth of shares (685 units at $0.22), increasing direct ownership by 2% to 31,979 units (SEC Form 4)